| __timestamp | Regeneron Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1271353000 | 11768000 |
| Thursday, January 1, 2015 | 1620577000 | 15152000 |
| Friday, January 1, 2016 | 2052295000 | 19828000 |
| Sunday, January 1, 2017 | 2075142000 | 25573000 |
| Monday, January 1, 2018 | 2186100000 | 23634000 |
| Tuesday, January 1, 2019 | 3036600000 | 38845000 |
| Wednesday, January 1, 2020 | 2735000000 | 50523000 |
| Friday, January 1, 2021 | 2908100000 | 75463000 |
| Saturday, January 1, 2022 | 3592500000 | 105767000 |
| Sunday, January 1, 2023 | 4439000000 | 167512000 |
| Monday, January 1, 2024 | 5132000000 |
Unlocking the unknown
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) investments are pivotal. Over the past decade, Regeneron Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have demonstrated contrasting yet intriguing R&D trajectories.
Regeneron, a leader in the industry, has consistently increased its R&D spending, culminating in a remarkable 250% growth from 2014 to 2023. This surge underscores their commitment to innovation and maintaining a competitive edge. In contrast, Xenon Pharmaceuticals, while smaller in scale, has shown a significant upward trend, with a nearly 14-fold increase in R&D expenses over the same period.
These investments reflect broader industry trends where strategic R&D funding is crucial for breakthroughs in drug development. As we look to the future, the commitment of these companies to R&D will likely continue to shape the biopharmaceutical landscape.
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viatris Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Verona Pharma plc
Regeneron Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and PTC Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Research and Development: Comparing Key Metrics for GSK plc and Xenon Pharmaceuticals Inc.
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: BeiGene, Ltd. vs Xenon Pharmaceuticals Inc.
Research and Development Investment: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Xenon Pharmaceuticals Inc.